MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice

Neuropharmacology

Volumn 92, Issue , 2015, Pages 170-182

  Rammes, Gerhard ^a   Gravius, Andreas ^b   Ruitenberg, Maarten ^b   Wegener, Nico ^b   Chambon, Caroline ^b   Sroka Saidi, Kamila ^b   Jeggo, Ross ^c   Staniaszek, Lydia ^c   Spanswick, Dave ^c,d,e   O'Hare, Eugene ^f   Palmer, Philip ^f   Kim, Eun Mee ^g   Bywalez, Wolfgang ^h   Egger, Veronica ^h,i   Parsons, Christopher G ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c NEUROSOLUTIONS LTD   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g UNIVERSITY OF ULSTER   (United Kingdom)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Aggregation; Alternating lever cyclic ratio schedule (ALCR); Alzheimer's disease; Beta amyloid; Calcium imaging; Dendritic spines; In vitro; In vivo; Long term potentiation (LTP); Novel object recognition (NOR); Oligomers; Pharmacokinetics; Synaptotoxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DIPEPTIDE DERIVATIVE; MRZ 99030; UNCLASSIFIED DRUG; 2-(2-AMINO-3-(1H-INDOL-3-YL)PROPIONYLAMINO)-2-METHYLPROPIONIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CALCIUM; CULTURE MEDIUM; DIPEPTIDE; INOSITOL; PEPTIDE FRAGMENT; SCYLLITOL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; COGNITION; CONTROLLED STUDY; DENDRITIC SPINE; DRUG BRAIN LEVEL; HIPPOCAMPAL CA1 REGION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; STOICHIOMETRY; TOXICITY TESTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COGNITION DISORDERS; CULTURE MEDIUM; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; INSTRUMENTAL CONDITIONING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NERVE CELL; PHARMACOLOGY; PHYSIOLOGY; PUTAMEN; RECOGNITION; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; COGNITION DISORDERS; CONDITIONING, OPERANT; CULTURE MEDIA, CONDITIONED; DIPEPTIDES; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; IN VITRO TECHNIQUES; INJECTIONS, INTRAVENTRICULAR; INOSITOL; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; NEURONS; PEPTIDE FRAGMENTS; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; RECOGNITION (PSYCHOLOGY);

EID: 84923551817     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.12.037     Document Type: Article

References (84)

1. P.A. Adlard, R.A. Cherny, D.I. Finkelstein, E. Gautier, E. Robb, M. Cortes, I. Volitakis, X. Liu, J.P. Smith, K. Perez, K. Laughton, Q.X. Li, S.A. Charman, J.A. Nicolazzo, S. Wilkins, K. Deleva, T. Lynch, G. Kok, C.W. Ritchie, R.E. Tanzi, R. Cappai, C.L. Masters, K.J. Barnham, and A.I. Bush Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 59 1 2008 43 55
2. H. Amijee, and D.I. Scopes The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease J. Alzheimers Dis. 17 1 2009 33 47
3. W.W. Anderson, and G.L. Collingridge The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 108 1 2001 71 83
4. E.W. Baxter, W.J. Cummings, and R.E. Fournier Formation of a large, complex domain of histone hyperacetylation at human 14q32.1 requires the serpin locus control region Nucleic Acids Res. 33 10 2005 3313 3322
5. K.F. Bell, and A. Claudio Cuello Altered synaptic function in Alzheimer's disease Eur. J. Pharmacol. 545 1 2006 11 21
6. I. Bezprozvanny, and M.P. Mattson Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease Trends Neurosci 31 9 2008 454 463
7. H. Braak, E. Braak, and J. Bohl Staging of Alzheimer-related cortical destruction Eur. Neurol. 33 6 1993 403 408
8. R. Cappai, and K.J. Barnham Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity Neurochem. Res. 33 3 2008 526 532
9. C. Chambon, N. Wegener, A. Gravius, and W. Danysz Behavioural and cellular effects of exogenous amyloid-beta peptides in rodents Behav. Brain Res. 225 2 2011 623 641
10. C. Chambon, N. Wegener, A. Gravius, and W. Danysz A new automated method to assess the rat recognition memory: validation of the method Behav. Brain Res. 222 1 2011 151 157
11. M. Citron Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discov. 9 5 2010 387 398
12. J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, and K.H. Ashe Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function Nat. Neurosci. 8 1 2005 79 84
13. W. Danysz, and C.G. Parsons The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence Int. J. Geriatr. Psychiatry 18 Suppl. 1 2003 S23 S32
14. W. Danysz, and C.G. Parsons Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine-searching for the connections Br. J. Pharmacol. 167 2 2012 324 352
15. R.C. Davis, I.T. Marsden, M.T. Maloney, L.S. Minamide, M. Podlisny, D.J. Selkoe, and J.R. Bamburg Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation Mol. Neurodegener. 6 2011 10
16. D. Dominguez, J. Tournoy, D. Hartmann, T. Huth, K. Cryns, S. Deforce, L. Serneels, I.E. Camacho, E. Marjaux, K. Craessaerts, A.J. Roebroek, M. Schwake, R. D'Hooge, P. Bach, U. Kalinke, D. Moechars, C. Alzheimer, K. Reiss, P. Saftig, and B. De Strooper Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice J. Biol. Chem. 280 35 2005 30797 30806
17. T.B. Durham, and T.A. Shepherd Progress toward the discovery and development of efficacious BACE inhibitors Curr. Opin. Drug Discov. Develop. 9 6 2006 776 791
18. R.M. Dutescu, Q.X. Li, J. Crowston, C.L. Masters, P.N. Baird, and J.G. Culvenor Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease Graefes Arch. Clin. Exp. Ophthalmol. 247 9 2009 1213 1221
19. V. Egger, and O. Stroh Calcium buffering in rodent olfactory bulb granule cells and mitral cells J. Physiol. 587 Pt 18 2009 4467 4479
20. G. Evin, M.F. Sernee, and C.L. Masters Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies CNS Drugs 20 5 2006 351 372
21. 2+ in hippocampal slices Neuropharmacology 38 9 1999 1253 1259
22. A. Frydman-Marom, M. Rechter, I. Shefler, Y. Bram, D.E. Shalev, and E. Gazit Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies Angew. Chem. Int. Ed. Engl. 48 11 2009 1981 1986
23. A. Frydman-Marom, R. Shaltiel-Karyo, S. Moshe, and E. Gazit The generic amyloid formation inhibition effect of a designed small aromatic beta-breaking peptide Amyloid 18 3 2011 119 127
24. S. Funke, T. van Groen, I. Kadish, D. Bartnik, L. Nagel-Steger, O. Brener, T. Sehl, R. Batra-Safferling, C. Moriscot, G. Schoehn, A.H.C. Horn, A. Müller-Schiffmann, C. Korth, H. Sticht, and D. Willbold Oral treatment with the d-Enantiomeric peptide D3 improves the pathology and behavior of Alzheimers disease transgenic mice ACS Chem. Neurosci. 1 9 2010 639 648
25. P. Garzone, M. Koller, A. Pastrak, S.S. Jhee, L. Ereshefsky, S. Moran, J.M. Cedarbaum, V. Xu, and B. Ross Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men Alzheimer's Dementia J. Alzheimer's Assoc. 5 4 2009 P323
26. C.C. Glabe Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta Subcell. Biochem. 38 2005 167 177
27. A.J. Granger, and R.A. Nicoll Expression mechanisms underlying long-term potentiation: a postsynaptic view, 10 years on Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 1633 2014 20130136
28. K.N. Green, and F.M. LaFerla Linking calcium to Abeta and Alzheimer's disease Neuron 59 2 2008 190 194
29. T. Guo, and D.W. Hobbs Development of BACE1 inhibitors for Alzheimer's disease Curr. Med. Chem. 13 15 2006 1811 1829
30. C. Haass, and D.J. Selkoe Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat. Rev. Mol. Cell. Biol. 8 2 2007 101 112
31. J. Hardy Amyloid, the presenilins and Alzheimer's disease Trends Neurosci. 20 4 1997 154 159
32. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 2002 353 356
33. K. Heininger A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes Hum. Psychopharmacol. 14 8 1999 525 581
34. N. Herrmann, S.A. Chau, I. Kircanski, and K.L. Lanctot Current and emerging drug treatment options for Alzheimer's disease: a systematic review Drugs 71 15 2011 2031 2065
35. N.W. Hu, T. Ondrejcak, and M.J. Rowan Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances Pharmacol. Biochem. Behav. 100 4 2012 855 862
36. B.P. Imbimbo Therapeutic potential of gamma-secretase inhibitors and modulators Curr. Top. Med. Chem. 8 1 2008 54 61
37. W.L. Klein Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets Neurochem. Int. 41 5 2002 345 352
38. W.L. Klein, G.A. Krafft, and C.E. Finch Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24 4 2001 219 224
39. N. Kokkoni, K. Stott, H. Amijee, J.M. Mason, and A.J. Doig N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure Biochemistry 45 32 2006 9906 9918
40. K.V. Kuchibhotla, S.T. Goldman, C.R. Lattarulo, H.Y. Wu, B.T. Hyman, and B.J. Bacskai Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks Neuron 59 2 2008 214 225
41. J. Kumar, and V. Sim D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease Prion 8 1 2014 119 124
42. P.N. Lacor, M.C. Buniel, P.W. Furlow, A.S. Clemente, P.T. Velasco, M. Wood, K.L. Viola, and W.L. Klein Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease J. Neurosci. 27 4 2007 796 807
43. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, and W.L. Klein Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. U.S.A. 95 11 1998 6448 6453
44. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, and K.H. Ashe A specific amyloid-beta protein assembly in the brain impairs memory Nature 440 7082 2006 352 357
45. M.J. Macdougall, and A. Fine The expression of long-term potentiation: reconciling the preists and the postivists Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 1633 2014 20130135
46. S.A. Mandel, T. Amit, O. Weinreb, L. Reznichenko, and M.B. Youdim Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases CNS Neurosci. Ther. 14 4 2008 352 365
47. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 7 2010 702 716
48. M. Maravall, Z.F. Mainen, B.L. Sabatini, and K. Svoboda Estimating intracellular calcium concentrations and buffering without wavelength ratioing Biophys. J. 78 5 2000 2655 2667
49. J.M. Mc Donald, G.M. Savva, C. Brayne, A.T. Welzel, G. Forster, G.M. Shankar, D.J. Selkoe, P.G. Ince, D.M. Walsh Medical Research Council Cognitive, F. and Ageing, S The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia Brain 133 Pt 5 2010 1328 1341
50. S.J. McKinnon Glaucoma: ocular Alzheimer's disease? Front. Biosci. 8 2003 s1140 1156
51. J. McLaurin, M.E. Kierstead, M.E. Brown, C.A. Hawkes, M.H. Lambermon, A.L. Phinney, A.A. Darabie, J.E. Cousins, J.E. French, M.F. Lan, F. Chen, S.S. Wong, H.T. Mount, P.E. Fraser, D. Westaway, and P. St George-Hyslop Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model Nat. Med. 12 7 2006 801 808
52. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, and F.M. LaFerla Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 3 2003 409 421
53. R.E. Olson, and C.F. Albright Recent progress in the medicinal chemistry of gamma-secretase inhibitors Curr. Top. Med. Chem. 8 1 2008 17 33
54. K. Parameshwaran, M. Dhanasekaran, and V. Suppiramaniam Amyloid beta peptides and glutamatergic synaptic dysregulation Exp. Neurol. 210 1 2008 7 13
55. C.G. Parsons, W. Danysz, A. Dekundy, and I. Pulte Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease Neurotox. Res. 24 3 2013 358 369
56. C.G. Parsons, M. Ruitenberg, C. Freitag, K. Sroka-Saidi, H. Russ, and G. Rammes MRZ-99030-a novel modulator of Aβ aggregation: I - mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD) Neuropharmacology 92 2015 158 169 10.1016/j.neuropharm.2014.1012.1038
57. C.G. Parsons, A. Stoffler, and W. Danysz Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse Neuropharmacology 53 2007 699 723
58. G. Paxinos, C. Watson, M. Pennisi, and A. Topple Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight J. Neurosci. Methods 13 2 1985 139 143
59. M.B. Podlisny, B.L. Ostaszewski, S.L. Squazzo, E.H. Koo, R.E. Rydell, D.B. Teplow, and D.J. Selkoe Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture J. Biol. Chem. 270 16 1995 9564 9570
60. M.B. Podlisny, D.M. Walsh, P. Amarante, B.L. Ostaszewski, E.R. Stimson, J.E. Maggio, D.B. Teplow, and D.J. Selkoe Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red Biochemistry 37 11 1998 3602 3611
61. D. Puzzo, L. Privitera, E. Leznik, M. Fa, A. Staniszewski, A. Palmeri, and O. Arancio Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus J Neurosci 28 53 2008 14537 14545
62. G. Rammes, A. Hasenjager, K. Sroka-Saidi, J.M. Deussing, and C.G. Parsons Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices Neuropharmacology 60 6 2011 982 990
63. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, M. Runfeldt, R.D. Shytle, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res. 1214 2008 177 187
64. T. Sato, K. Ananda, C.I. Cheng, E.J. Suh, S. Narayanan, and M.S. Wolfe Distinct pharmacological effects of inhibitors of signal peptide peptidase and gamma-secretase J. Biol. Chem. 283 48 2008 33287 33295
65. D. Selkoe, and R. Kopan Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration Annu Rev. Neurosci. 26 2003 565 597
66. D.J. Selkoe Resolving controversies on the path to Alzheimer's therapeutics Nat. Med. 17 9 2011 1060 1065
67. D.J. Selkoe Preventing Alzheimer's disease Science 337 6101 2012 1488 1492
68. G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F.M. Brett, M.A. Farrell, M.J. Rowan, C.A. Lemere, C.M. Regan, D.M. Walsh, B.L. Sabatini, and D.J. Selkoe Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat. Med. 14 8 2008 837 842
69. M. Sheng, B.L. Sabatini, and T.C. Sudhof Synapses and Alzheimer's disease Cold Spring Harb. Perspect. Biol. 4 5 2012
70. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, and R. Katzman Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30 4 1991 572 580
71. M. Townsend, J.P. Cleary, T. Mehta, J. Hofmeister, S. Lesne, E. O'Hare, D.M. Walsh, and D.J. Selkoe Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers Ann. Neurol. 60 6 2006 668 676
72. M. Townsend, G.M. Shankar, T. Mehta, D.M. Walsh, and D.J. Selkoe Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers J. Physiol. 572 Pt 2 2006 477 492
73. J.W. Um, A.C. Kaufman, M. Kostylev, J.K. Heiss, M. Stagi, H. Takahashi, M.E. Kerrisk, A. Vortmeyer, T. Wisniewski, A.J. Koleske, E.C. Gunther, H.B. Nygaard, and S.M. Strittmatter Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein Neuron 79 5 2013 887 902
74. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 6880 2002 535 539
75. D.M. Walsh, and D.J. Selkoe Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 44 1 2004 181 193
76. D.M. Walsh, M. Townsend, M.B. Podlisny, G.M. Shankar, J.V. Fadeeva, O. El Agnaf, D.M. Hartley, and D.J. Selkoe Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation J. Neurosci. 25 10 2005 2455 2462
77. M.J. Wesierska, W. Duda, and C.A. Dockery Low-dose memantine-induced working memory improvement in the allothetic place avoidance alternation task (APAAT) in young adult male rats Front. Behav. Neurosci. 7 2013 203
78. A.R. White, T. Du, K.M. Laughton, I. Volitakis, R.A. Sharples, M.E. Xilinas, D.E. Hoke, R.M. Holsinger, G. Evin, R.A. Cherny, A.F. Hill, K.J. Barnham, Q.X. Li, A.I. Bush, and C.L. Masters Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity J. Biol. Chem. 281 26 2006 17670 17680
79. N.K. Woods, and J. Padmanabhan Neuronal calcium signaling and Alzheimer's disease Adv. Exp. Med. Biol. 740 2012 1193 1217
80. B.A. Yankner Mechanisms of neuronal degeneration in Alzheimer's disease Neuron 16 5 1996 921 932
81. J.T. Yu, R.C. Chang, and L. Tan Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities Prog. Neurobiol. 89 3 2009 240 255
82. W. Zajaczkowski, T. Frankiewicz, C.G. Parsons, and W. Danysz Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP Neuropharmacology 36 7 1997 961 971
83. T. Zhang, J. Zhang, P. Derreumaux, and Y. Mu Molecular mechanism of the inhibition of EGCG on the Alzheimer Abeta(1-42) dimer J. Phys. Chem. B 117 15 2013 3993 4002
84. P.R. Zoladz, A.M. Campbell, C.R. Park, D. Schaefer, W. Danysz, and D.M. Diamond Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane Pharmacol. Biochem. Behav. 85 2 2006 298 306